As of 2026-01-05, the Relative Valuation of VistaGen Therapeutics Inc (VTGN) is (22.09) USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.68 USD, the upside of VistaGen Therapeutics Inc based on Relative Valuation is -3352.7%.
The range of the Relative Valuation is (17.67) - (23.72) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.2x - 19.3x | 17.8x |
| Forward P/E multiples | 14.4x - 21.7x | 18.1x |
| Fair Price | (17.67) - (23.72) | (22.09) |
| Upside | -2702.2% - -3593.7% | -3352.7% |
| Date | P/E |
| 2026-01-02 | -0.55 |
| 2025-12-31 | -0.54 |
| 2025-12-30 | -0.55 |
| 2025-12-29 | -0.54 |
| 2025-12-26 | -0.59 |
| 2025-12-24 | -0.59 |
| 2025-12-23 | -0.58 |
| 2025-12-22 | -0.61 |
| 2025-12-19 | -0.63 |
| 2025-12-18 | -0.60 |
| 2025-12-17 | -0.70 |
| 2025-12-16 | -3.54 |
| 2025-12-15 | -3.57 |
| 2025-12-12 | -3.45 |
| 2025-12-11 | -3.21 |
| 2025-12-10 | -3.68 |
| 2025-12-09 | -3.70 |
| 2025-12-08 | -3.49 |
| 2025-12-05 | -3.52 |
| 2025-12-04 | -3.48 |
| 2025-12-03 | -3.03 |
| 2025-12-02 | -2.93 |
| 2025-12-01 | -3.60 |
| 2025-11-28 | -3.98 |
| 2025-11-26 | -3.69 |
| 2025-11-25 | -3.81 |
| 2025-11-24 | -3.84 |
| 2025-11-21 | -3.73 |
| 2025-11-20 | -3.62 |
| 2025-11-19 | -3.66 |
| 2025-11-18 | -3.76 |
| 2025-11-17 | -3.59 |
| 2025-11-14 | -3.09 |
| 2025-11-13 | -3.09 |
| 2025-11-12 | -3.31 |
| 2025-11-11 | -3.28 |
| 2025-11-10 | -3.23 |
| 2025-11-07 | -3.24 |
| 2025-11-06 | -3.27 |
| 2025-11-05 | -3.40 |
| 2025-11-04 | -3.31 |
| 2025-11-03 | -3.45 |
| 2025-10-31 | -3.20 |
| 2025-10-30 | -3.05 |
| 2025-10-29 | -3.22 |
| 2025-10-28 | -3.29 |
| 2025-10-27 | -3.17 |
| 2025-10-24 | -3.31 |
| 2025-10-23 | -3.38 |
| 2025-10-22 | -3.33 |